Results 211 to 220 of about 3,766,051 (278)

Antianginal drugs. Part II. Human pharmacology of nitroglycerin

American Heart Journal, 1966
Solomon Fisch
openalex   +4 more sources

Antianginal drugs. Part III. Clinical use of nitroglycerin

American Heart Journal, 1966
Solomon Fisch
openalex   +4 more sources

Systemic vascular pooling potency of vasodilator drugs (nitroglycerin, phentolamine, hydralazine)

American Heart Journal, 1979
B. E. Strauer, A. Scherpe
openalex   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Lysozyme and Human Serum Albumin Proteins as Potential Nitric Oxide Cardiovascular Drug Carriers: Theoretical and Experimental Investigation.

Journal of Physical Chemistry B, 2021
Nitric oxide-containing drugs present a critical remedy for cardiovascular diseases. Nitroglycerin (NG, O-NO) and S-nitrosoglutathione (SNG, S-NO) are the most common nitric oxide drugs for cardiovascular diseases. Insights regarding the binding affinity
C. Nassab, Mahreen Arooj, Ihsan A. Shehadi, Javad B. M. Parambath, S. Kanan, Ahmed Abouzeed Mohamed   +5 more
semanticscholar   +1 more source

Liquid Chromatographic Method Development for Quantification of Inorganic Nitrite and Nitrate Impurities from Nitroglycerin Drug Substance by Using Ion-Pair Reagents with Liquid-Liquid Extraction Technique.

Journal of Chromatographic Science, 2019
A large number of laboratory studies have reported Nitrite (NO2-) and Nitrate (NO3-) to be among the most common degradation products of the high-explosive Nitroglycerin drug substance.
Pritesh Desai, P. Mehta, Avani Chokshi
semanticscholar   +1 more source

Transdermal Drug Delivery Systems (TDDS): Recent Advances and Failure Modes.

Molecular Pharmaceutics
Transdermal drug delivery systems (TDDS), commonly refered to as "patches", present a nonintrusive technique to provide medication without the need for invasive procedures.
Mohsen Ghaferi, S. Alavi, Khanh Phan, H. Maibach, Y. Mohammed   +4 more
semanticscholar   +1 more source

Oral nitroglycerin as a prophylactic antianginal drug: Clinical, physiologic, and statistical evidence of efficacy based on a three-phase experimental design

American Heart Journal, 1975
Travis Winsor, Harvey J. Berger
openalex   +2 more sources

Pulsed release of nitroglycerin from transdermal drug delivery systems

International Journal of Pharmaceutics, 1999
To achieve a discontinuous drug delivery to the skin a new actively controlled transdermal system has been developed. The system consists of a tube shaped drug reservoir in combination with an electronic circuit and a gas producing cell. A magnetic switch was used to control the onset of the production of hydrogen gas.
R. Gröning, U Kuhland
openaire   +3 more sources

Nitroglycerin ameliorates liver injury and regulates adaptive immunity in mice.

Drug development research (Print), 2020
This study aimed to assess the protective effect of nitroglycerin, a commonly used drug in cardiovascular diseases, on mice with acute liver injury induced by carbon tetrachloride (CCl4 ). The mice were randomly divided into three groups: control, CCl4 ,
Shuang Zhao, Zhong-Hua Lu, Juanjuan Cui, Dong Li, Yi-ling Zhu, J. Gan   +5 more
semanticscholar   +1 more source

A New Topical Drug Delivery System for Nitroglycerin

1981
Nitroglycerin has been the agent of choice for the treatment of angina pectoris for over 100 years. In recent years various long-acting preparations have been introduced for the prophylaxis of angina pectoris and most recently for use in the long term management of a patient with left ventricular dysfunction.
J. Brymer, A. Golub, J. Walton, A. Keith, B. Lucchesi, H. Colfer, P. Stetson, B. Pitt   +7 more
openaire   +2 more sources